The Rater Applied Performance Scale: development and reliability

被引:32
作者
Lipsitz, J
Kobak, K
Feiger, A
Sikich, D
Moroz, G
Engelhardt, N
机构
[1] Columbia Univ, Coll Phys & Surg, New York State Psychiat Inst, Anxiety Clin 69, New York, NY 10032 USA
[2] Res Training Associates, Madison, WI USA
[3] Dean Fdn, Madison, WI USA
[4] Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA
[5] Hoffmann La Roche Pharmaceut, Nutley, NJ USA
[6] Indianapolis Sch Med, Indianapolis, IN USA
关键词
Rater Applied Performance Scale; clinical trial; independent evaluator; reliability; depression; methodology; psychometrics;
D O I
10.1016/j.psychres.2004.03.001
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Previous studies of rater performance and interrater reliability have used passive scoring tasks such as rating patients from a videotaped interview. Little is known, however, about how well raters conduct assessments on real patients or how reliably they apply scoring criteria during actual assessment sessions. With growing recognition of the importance of monitoring and review of actual evaluation sessions, there is need for a systematic approach to quantify raters' applied performance. The Rater Applied Performance Scale (RAPS) measures six dimensions of rater performance (adherence. follow-up, clarification, neutrality, rapport, and accuracy) based on reviews of audiotaped or videotaped assessment sessions or on live monitoring of assessment sessions. We tested this new scale by having two reviewers rate 20 Hamilton Depression Scale rating sessions ascertained from a multi-site depression trial. We found good internal consistency for the RAPS. Interrater (i.e. inter-reviewer) reliability was satisfactory for RAPS total score ratings. In addition, RAPS ratings correlated with quantitative measures of scoring accuracy based on independent expert ratings. Preliminary psychometric data suggest that the RAPS may be a valuable tool for quantifying the performance of clinical raters. Potential applications of the RAPS are considered. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:147 / 155
页数:9
相关论文
共 17 条
[1]  
ANDREASEN NC, 1982, AM J PSYCHIAT, V139, P876
[2]   Assessment of reliability in the clinical evaluation of depressive symptoms among multiple investigators in a multicenter clinical trial [J].
Baca-García, E ;
Blanco, C ;
Sáiz-Ruiz, J ;
Rico, F ;
Diaz-Sastre, C ;
Cicchetti, DV .
PSYCHIATRY RESEARCH, 2001, 102 (02) :163-173
[3]   A general system for evaluating therapist adherence and competence in psychotherapy research in the addictions [J].
Carroll, KM ;
Nich, C ;
Sifry, RL ;
Nuro, KF ;
Frankforter, TL ;
Ball, SA ;
Fenton, L ;
Rounsaville, BJ .
DRUG AND ALCOHOL DEPENDENCE, 2000, 57 (03) :225-238
[4]  
Demitrack MA, 1998, PSYCHOPHARMACOL BULL, V34, P19
[5]  
FEIGER AD, 2001, 41 ANN M PHOEN AZ
[6]  
FRANK E, 1991, ARCH GEN PSYCHIAT, V48, P1053
[7]   Out of the box [J].
Gelenberg, AJ .
ARCHIVES OF GENERAL PSYCHIATRY, 2002, 59 (03) :281-281
[8]  
HOLLON SD, 1984, FINAL REPORT SYSTEM, V37, P509
[9]   Enhancing the technology of clinical trials and the trials model to evaluate newly developed, targeted antidepressants [J].
Katz, MM ;
Halbreich, UM ;
Bowden, CL ;
Frazer, A ;
Pinder, RM ;
Rush, AJ ;
Wheatley, DP ;
Lebowitz, BD .
NEUROPSYCHOPHARMACOLOGY, 2002, 27 (03) :319-328
[10]   Are placebo controls necessary to test new antidepressants and anxiolytics? [J].
Khan, A ;
Khan, S ;
Brown, WA .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2002, 5 (03) :193-197